An Bioequivalence Study of Loxoprofen Sodium Patches in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06510413
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 1336
- Registration Number
- NCT05675072
- Locations
- 🇨🇳
Shenzhen Third People's Hospital, Shenzhen, Guangdong, China
A Study of FB2001 for Inhalation in Healthy Chinese Adults
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05583812
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, China
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 1188
- Registration Number
- NCT05445934
- Locations
- 🇨🇳
Huashan Hospital Fudan University, Shanghai, Shanghai, China
🇨🇳Beijing Ditan Hospital Capital Medical University, Beijing, China
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05206019
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, China
A Bridging Study of FB2001 in Healthy Subjects
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05197179
- Locations
- 🇨🇳
Shanghai Xuhui Central Hospital, Shanghai, China
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04819347
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT04766931
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04560569
- Locations
- 🇺🇸
ABT-3BNC117_203 Investigational Site, Saint Louis, Missouri, United States
Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2020-03-30
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT03997734
- Locations
- 🇨🇳
The Third People's Hospital of Wuxi, Wuxi, Jiangsu, China
© Copyright 2024. All Rights Reserved by MedPath